DLA Piper has advised Copernicus, regarded as one of the most valued innovative companies in the Polish health sector, and its founders on its sale to Nemera, a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries.
Founded in Poland 2004, Copernicus specializes in the development and manufacturing of drug delivery services and devices. Copernicus’ range of reusable and disposable pen injectors is tailored for the treatment of various chronic pathologies. Copernicus provides a comprehensive range of services in the introduction of modern and intuitive parenteral drug delivery devices.
Nemera provides the most comprehensive range of devices in the industry, including off-the-shelf innovative systems, customized design development and GMP manufacturing of devices developed by their customers.
DLA Piper’s Corporate team in Warsaw was led by partner Jakub Domalik-Plakwicz and associate Michał Banasiak, who were supported by counsel Mateusz Zalenski and associate Klaudia Lorent. Alongside the DLA Piper team, Copernicus and founders were advised by Bartosz Świderski, Copernicus in-house lawyer.
